Cerebrolysin

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Severe renal impairment: the free amino acid component of Cerebrolysin (75% of the preparation) places a nitrogen load on renal clearance pathways; in subjects with severely reduced GFR, amino acid accumulation and metabolic byproduct buildup is a meaningful concern.
• Epilepsy or active seizure disorders: Cerebrolysin has been associated with lowering the seizure threshold in susceptible individuals through its neurostimulatory and glutamatergic modulatory activity; contraindicated in subjects with uncontrolled seizure disorders.
• Active status epilepticus: absolute contraindication.
• Known hypersensitivity to porcine-derived biological products: Cerebrolysin is derived from porcine brain; subjects with pork allergies or hypersensitivity to porcine proteins carry a risk of allergic reaction ranging from injection site reaction to systemic anaphylaxis.
• Active malignancy involving the CNS: neurotrophic growth factor activity (NGF, BDNF, GDNF) from Cerebrolysin could theoretically support tumor cell survival and proliferation in brain tumors expressing Trk receptors.
• Pregnancy: no clinical safety data; neurotrophic factor delivery during CNS development has not been established as safe.
• Breastfeeding: no safety data.
• Concurrent use with MAO inhibitors: potential pharmacodynamic interaction through serotonergic and noradrenergic modulation.
• Acute stroke during the hyperacute phase (first 4-6 hours): Cerebrolysin clinical protocols specify administration after the hyperacute window; early intervention timing is a clinical judgment requiring medical supervision.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Injection site soreness: the primary and most consistent adverse effect with IM administration; larger volume injections into muscle produce mechanical distension and mild inflammatory response; more pronounced with higher doses (20-32mg/day split IM); typically resolves within 24-48 hours.
• Mild flu-like symptoms: low-grade fever, malaise, mild chills; reported in a subset of users during the first 1-2 weeks of a new cycle; likely related to the immune response to the porcine-derived biological extract; typically self-limiting.
• Dizziness and lightheadedness: uncommon; reported in subjects receiving higher doses; mechanism not fully characterized; mild and transient.
• Nausea: mild; reported in a small subset; more common with faster injection rates; slow administration mitigates.
• Headache: uncommon; reported in the initial days; may reflect the rapid changes in neurotrophic factor signaling in cerebrovascular and neural tissue.
• Agitation or restlessness: paradoxical stimulant-like response in a small subset of users; the NGF-mediated cholinergic activation in some subjects produces heightened arousal rather than cognitive clarity; usually resolves within the first week.
• Allergic reactions: ranging from local injection site erythema and urticaria to (rarely) systemic allergic responses in porcine-sensitive subjects; the porcine biological origin is the source of this risk.
• Potential seizure threshold lowering: the primary serious adverse effect documented in clinical trial safety data; most relevant in subjects with pre-existing epileptiform activity; routine use in healthy subjects at standard doses is not associated with seizure induction.
• Insomnia: reported by a minority of subjects with morning IM or subcutaneous dosing, particularly at higher doses; related to neurostimulatory NGF/BDNF activation of arousal circuits; manage with strict morning administration.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• PubMed search: Cerebrolysin